• Explore /
  • Poster
  • / A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.

A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission.

Abstract Poster

Authors

Anna Pavlick

Anna C. Pavlick

Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY

Anna C. Pavlick , Ana Blazquez , Marcia Meseck , Michael J. Donovan , Mireia Castillo-Martin , Tin Htwe Thin , Rachel Sabado , John P. Mandeli , Sacha Gnjatic , Philip Adam Friedlander , Nina Bhardwaj

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02334735

Citation

J Clin Oncol 37, 2019 (suppl; abstr 9538)

DOI

10.1200/JCO.2019.37.15_suppl.9538

Abstract #

9538

Poster Bd #

109

Abstract Disclosures

Similar Posters

First Author: Nina Bhardwaj

First Author: Jonathan S. Cebon

First Author: Thomas Urban Marron

First Author: Max Mu Wang